2.1 C
Munich
Friday, April 19, 2024

Astellas Pharma agrees to buy Iveric Bio for $5.9 billion (NASDAQ:ISEE)

Must read

- Advertisement -


Macro photos of the human eye - cataract clouding of the lens, deterioration of vision. Treatment, surgery and ophthalmology

Zarina Lukash/iStock via Getty Images

Astellas Pharma Inc. (OTCPK:ALPMF) agreed to acquire Iveric Bio (NASDAQ:ISEE) for $5.9 billion to add ophthalmology capabilities to the Japanese pharmaceutical giant.

Under the agreement, Astellas (OTCPK:ALPMF) agreed to purchase Iveric Bio (ISEE) for $40 a share, representing a 22% premium to

- Advertisement -



Source link

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article